The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Giovanna Roncador, PhD

Giovanna Roncador, PhD

Speaker: Professor Giovanna Roncador obtained a Bachelor’s Degree in Biology from Bologna University in 1994, and a PhD degree in Biology from the Universidad Autónoma deMadrid in 2012. From 1994 to 1996 she was in charge of the routine diagnostic immunohistochemistry procedures in the diagnostic laboratory, as well as the immunophenotypic characterization of lymphomas for research projects, at the Department of Haemolymphopathology of Bologna University. In 1997 she moved to the Nuffield Department of Clinical Laboratory Sciences at Oxford University, where she specialized in monoclonal antibodies (mAbs) technology, focusing in the production and characterization of mAbs for the diagnosis of lymphomas. In October 2000 Dr. Roncador joined the CNIO as Head of the Monoclonal Antibodies Unit, to set up the monoclonal antibodies technology at this institution, supervising a team of 3-4 technicians. The technical and scientific excellence of the Unit is evidenced by its trajectory of more than 19 years, resulting in the production of ~ 150 mAbs, mostly directed against markers used for research and diagnosis of cancer. This work has resulted in the publication of a total of 78 research articles in peer-reviewed journals of international relevance, where she is co-author or corresponding author. She has supervised one doctoral thesis, and is involved in different activities related to the training and education of young researchers and technicians. Since 2009 she is the founder and chair of EuroMabNet (www.euromabnet.con), the first  European non-profit organization of multidisciplinary academic laboratories with internationally recognized reputations in generating and using validated monoclonal antibodies.

Professor Roncador is also deeply involved in activities of technology transfer: 40 of the high-quality antibodies produced by the Unit since 2005 have been licensed to the most prestigious international companies operating in this field, such as BD Bioscience, eBioscience, Biolegend, Sigma, Abcam, Millipore, generating an important economic return for the CNIO in royalties. Each year the Unit releases a catalog of antibodies available for licensing (more than 100), containing their validation data (accessible at http://www.cnio.es/ing/servicios/anticuerpos/default.Aspx and https://www.cnio.es/es/servicios/anticuerpos/datasheet.aspx). The antibodies produced by the Unit have been applied as valuable tools for cancer research and diagnosis, both in hospitals of the National Health System and in national and international research institutions. In addition, Professor Roncador has established collaborations with pharmaceutical and biotech companies (Merck, Lilly, R-Biopharm) for the production of antibodies against molecules involved in cancer development.

 

Dr. Simon Goodman moderates this webinar series.

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • FDA approves Zynyz™ (retifanlimab-dlwr) for Merkel cell carcinoma March 23, 2023
  • Ultralong CDR H3-based knobs: the smallest antibody fragment March 6, 2023
  • TRUST4 is now certified as AIRR-compliant March 1, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals